辣椒(Capsicum annuum L.)在整个巴西领土上种植,这要归功于大型消费者,东南地区是主要生产。这是国家园艺市场中10个最高的生态蔬菜之一,但在文化疗法和许多静脉中的要求很高,受到害虫攻击的伤害。在其中,我们强调了白螨[polyphagotarsonemus latus(banks)(acari:tarsonemidae)],由于其在几个生产区域中的频繁和严重发生,这已成为注意力的目标。白螨分布在热带地区,也分布在温带地区,已记录在大量农业,观赏和野生物种中(Jeppson等人,1975年; Brown&Jones,1983年; Li等,1985;格森,1992年; Fan&Petit,1994)。在胡椒中,它的不一致在实践中已经被标记为全世界(Hambleton,1938; Cross,1979; Li等人,1985;格森,1986年;大卫,1986年; Roditakis&Drossos,1987)。
电子邮件:julia.araujo-98@hotmail.com摘要糖尿病性酮症酸中毒(CAD)和高血糖高渗透状态(EHH)是具有不同临床表现的医学紧急情况,需要精确诊断。CAD的特征是胃肠道症状,急性代谢疾病,可以在不到24小时内触发,通常与急性腹部混淆。另一方面,EHH具有嗜睡,昏迷和癫痫发作等突出的神经系统表现形式,并且通常是阴性地发生的,具有极高的血糖。鉴别诊断是基本的,具体取决于特定的实验室标准。治疗管理涵盖了通过液体疗法校正脱水,仔细替换钾,以避免低钙血症和胰岛素给药,以恢复血糖正常化和代谢异常的纠正。选择
我们有幸得到了国内外作家的贡献,他们始终表现出兴趣和动力,将这些知识收集并组织到一个地方。我们感谢大家同意为这本在巴西才刚刚开始对话的书做出贡献。非常高兴能够与已经参与 IAIE 国际辩论的外国作家建立这样的对话:Vivienne Bath、Tim D. Ellemann、Steffen Hindelang、Andreas Moberg、Santosh Pai、Ji Ma 和 Manu Misra。我们还要感谢 Sarah Danzman,尽管她在研究期间是一位对话者,但她未能贡献一章内容,但却为我们提供了与 Sophie Meunier 合作开发的完整 Prism 数据库。我们还要感谢巴西作家卡洛斯·马尔西奥·科森德 (Carlos Márcio Cozendey),他是国际投资体系具体辩论的关键人物。
摘要肥胖是一种迅速传播的流行病。已经成为公共卫生问题。因此,出现了几种针对体重减轻的饮食。本研究的目的是探索体重减轻的不同饮食:低碳水化合物,间歇性和生酮禁食。本研究是对过去10年的书目回顾,使用葡萄牙语和英语中的健康描述符,以及以公共卫生而广为人知的科学期刊。生酮饮食成为实现大量体重减轻的安全选择,但应在整体医疗监督下成为策略的一部分。已经发现,间歇性禁食可以改善与代谢综合征相关的代谢标记,但是在其有效性,长期效果和安全性上存在不确定性,因此有必要使用个性化方法。,如果正确执行的碳水化合物饮食可有效减轻体重减轻体重,但甘油三酸酯,血糖控制和高密度脂蛋白(HDL)水平增加。,但平衡的常规饮食仍然是最安全的治疗方式。因此,重要的是,在选择其中一种饮食之前,个人首先接受营养评估,以了解这些饮食中的哪种最适合您。关键字:超重;减轻体重;生酮饮食;间歇性禁食。摘要肥胖是一种快速传播的流行病。有成为公共卫生问题。结果,已经出现了一些针对体重减轻的饮食。因此,这项研究的目的是研究减肥的不同饮食:低碳水化合物,间歇性禁食和生酮。本研究是对过去10年的书目综述,使用葡萄牙语和英语中的健康描述符,以及以公共卫生众所周知的科学期刊。生酮饮食是实现大量体重减轻的安全选择,但在全面的医疗监督下,它们必须成为战略的一部分。发现间歇性禁食可以改善与代谢综合征相关的代谢标记,但是关于其有效性,长期效果和安全性存在不确定性,这就是为什么需要使用个性化方法的原因。,尽管低碳水化合物饮食可有效减轻体重,甘油三酸酯,血糖控制和如果正确执行的HDL水平升高。但常规平衡饮食仍然是最安全的治疗方式。因此,重要的是,在选择其中一种饮食之前,个人首先接受营养评估,以了解这些饮食中的哪种最适合其情况。关键字:超重;减轻体重;饮食生酮;间歇性禁食。恢复la obesidad es una epidemia que se propagarápidamente。habiéndoseconvertido en un solicea de saludpública。Como Resultado,Han Surgido Varias Dietas Destinadas a Perder Peso。Por Ello,El objetivo de este este estudio fue estudiar las diferentes dietas dietas para adelgazar:baja en carbohidratos,ayuno intermitentente ycetogénica。本研究是对过去10年的书目回顾,使用葡萄牙语和英语中的健康描述符,以及公共卫生广泛知识的科学期刊。 div>生酮饮食是实现大量体重减轻的安全选择,但它们必须在整体医疗监督下成为战略的一部分。 div>发现间歇性禁食可以改善与代谢综合征相关的代谢标记,但是关于它们的有效性,长期和安全效应存在不确定性,因此有必要使用个性化方法。 div>,尽管低碳水化合物饮食可有效减轻体重,但 div>
抽象的慢性肾脏疾病(CKD)是由肾单位数量和功能的进行性和不可逆转的损失定义的3个月以上。众所周知,血液透析中有82%的CKD患者表现出至少一种皮肤胶质变化,并且可能对其生活质量产生负面影响。这项研究的目的是了解联邦地区血液透析服务中慢性肾脏人群的临床和流行病学特征,并评估这些患者主要皮肤病学表现的普遍性。这是一种描述性的,回顾性的病例系列类型,基于2019年8月至2020年1月的医疗记录,访谈和身体检查。包括46例患者,占女性的52%,主要年龄组在40至50岁之间。所有分析的患者均具有一定的皮肤病表现,重点是指甲变化(89.6%),疾病(83.3%)和粘膜变化(77.1%)。这些患者的临床和流行病学特征以及皮肤粘膜变化的研究对于早期诊断和干预至关重要。关键字:慢性肾衰竭;皮肤病;肾透析。摘要慢性肾脏疾病(CKD)被定义为肾单位数量和功能的进行性和不可逆转的损失超过3个月。这是一个公认的事实,有82%的CKD paties终于经历了一种皮肤或粘膜改变,这可能会对其生活质量产生负面影响。关键字:慢性肾脏疾病;皮肤疾病;肾透析。这项研究的目的是确定联邦地区血液透析服务中CKD人群的临床和流行病学特征,并评估这些患者主要皮肤病学表现的患病率。这是一项基于对2019年8月至2020年1月之间进行的医疗记录,访谈和身体检查的分析的描述性,回顾性的病例系列研究。总共包括46名患者,其中52%是女性,大多数年龄在40至50岁之间。所有经过分析的患者均表现出皮肤病学表现,特别着重于指甲改变(89.6%),疾病(83.3%)和粘膜改变(77.1%)。研究这些患者的临床和流行病学特征以及皮肤和粘膜改变,对于早期诊断和干预至关重要。恢复La Enfermedad肾脏Crónica(ERC)SE定义了Pordida Progresiva e不可逆的Elnúmeroy lafunciónde losnéfronesdurantemásdurantemásde 3 Meses。se sabe que el 82%de los pacientes con erc enhemodiálisissipiestan al anaos una a aailtaacióncutáneo-Mucosa,Pudiendo Generar generar Un Impact officment negoto negativo en su su su calidad de vida。el objetivo de este estudio fue conocer el perfilclínicoyepidemiológicodela lapoblaciónRenalCrónicaen un servicio dehemodiálisisdel
摘要简介:由于胸痛的病因不同,胸痛的初步处理对于急诊医生来说是一个具有挑战性的情况。为了确保有效的管理,我们制定了不同的评估协议。目的:确定急诊科(ED)成人胸痛非侵入性评估的临床评估方案。方法:研究按照PRISMA进行,并在PROSPERO平台上注册(CRD42024519268)。在包括 PubMed 和 SciELO 在内的国际数据库中进行了全面系统搜索,以查找截至 2024 年 4 月发表的文章。所有报告成人胸痛临床评估方案的相关文章均纳入分析。结果:本篇综述纳入了有关急诊科胸痛管理的指南和协议的文章。我们发现,急诊科胸痛的评估需要系统的方法。分析包括患者病史、体格检查、鉴别诊断、诊断测试和风险分层。研究还指出,12 导联心电图、肌钙蛋白水平升高以及 ADP、EDACS 和 HEART 协议在确定患者发生重大不良心脏事件的风险方面具有重要意义。结论:本文强调了在急诊科胸痛评估中使用循证协议和决策路径的重要性。它进一步强调了高敏肌钙蛋白检测和成像方式在快速准确诊断急性冠状动脉综合征等疾病中的作用。关键词:胸痛;急诊科;案件管理;评估协议;修订。摘要简介:由于胸痛的病因不同,胸痛的初步处理对于急诊医生来说是一个具有挑战性的情况。为了确保有效的管理,我们制定了不同的评估协议。目的:确定急诊科(ED)成人胸痛非侵入性化疗的临床评估方案。方法:本研究按照PRISMA进行,并在PROSPERO平台上注册(CRD42024519268)。我们对 PubMed 和 SciELO 等国际数据库进行了全面系统搜索,以查找截至 2024 年 4 月发表的文章。所有相关文章均报告了临床
简介:针对 2019 冠状病毒病 (COVID-19) 的不同疫苗的免疫反应在患有终末期肾病 (ESRD) 的患者中研究甚少,尤其是在中东和北非。我们进行了这项研究,以评估接受常规血液透析 (HD) 的 ESRD 患者接种 COVID-19 疫苗的有效性。 M 代表全部:在这项前瞻性观察研究中,我们招募了 60 名接受常规 HD 治疗且已完成 COVID-19 疫苗接种计划的 ESRD 患者和 30 名接种了疫苗的健康参与者。在完成疫苗接种计划一个月后对严重急性呼吸综合征冠状病毒 2 免疫球蛋白 G (SARS-COV2 IgG) 的血清水平进行了量化,并于 2021 年 10 月至 2022 年 3 月对所有参与者进行了随访。研究中使用的疫苗来自辉瑞-BioNTech、阿斯利康和国药集团。结果:HD 患者的 SARS-COV2 IgG 中位水平低于健康参与者(p < 0.001)。就 COVID-19 疫苗接种类型而言,HD 患者的 SARS-COV2 IgG 水平没有统计学差异。在观察期间,无一例 HD 患者感染 COVID-19。结论:COVID-19 疫苗接种似乎可有效保护 HD 患者 6 个月,并且疫苗副作用是可以忍受的。
Figura 1: Desenho esquemático dos componentes presentes nas redes extracelulares de DNA em neutrófilos ................................................................................................................................................17 Figura 2: Representação esquemática da via da Netose ........................................................................19 Figura 3: Desenho experimental .................................................................................................................28 Figura 4: Estratégia de análise para avaliar a frequência das populações de CD14+,CD19+, CD4+ e CD8+ após a Marcaçãocomanticorpos antisubpopulaçõescelulares eaquisiçãoporcitometriade fluxo。..................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 38图5:富集淋巴细胞的细胞组成的细胞仪分析。。...................................................................................................................................................39 Figura 6: Avaliação da porcentagem de morte celular por citometria de fluxo ................................... 40 Figure 7: Evaluation, in lymphocyte -enriched crops, by confocal microscopy, of the occurrence of extracellular DNA. 在 ................. 51 Figure 15: SME evaluation of CD4+ and CD8+ T lymphocytes................................... 40 Figure 7: Evaluation, in lymphocyte -enriched crops, by confocal microscopy, of the occurrence of extracellular DNA.在................. 51 Figure 15: SME evaluation of CD4+ and CD8+ T lymphocytes.................. 51 Figure 15: SME evaluation of CD4+ and CD8+ T lymphocytes........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ .......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 46 Figure 11: Extracellular networks blushed by DAPI do not have actin. ............................... 47 Figure 12 Electronic microscopy assessment of scanning the presence of extracellular networks in lymphocyte -enriched crops. .......................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在........................................... 46 Figure 11: Extracellular networks blushed by DAPI do not have actin................................ 47 Figure 12 Electronic microscopy assessment of scanning the presence of extracellular networks in lymphocyte -enriched crops. .......................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在............................... 47 Figure 12 Electronic microscopy assessment of scanning the presence of extracellular networks in lymphocyte -enriched crops........................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... ......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在.......................................................................... 50 Figure 13 Electronic Microscopy Evaluation of Internal Morphology Transmission of Lymphocytes................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ ........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................ 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry. .............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54 在......................................................... 52 Figure 16: Evaluation of the percentage of cell death by CD4+ and CD8+ T lymphocyte flow cytometry............................................................................................................................................................................................................................................................................................................................................................................................................................................................... 54 在.............................................................................................................................................................................................................................................................................................................................................................................................................................................................. 54在.............................................. 55 Figure 18 Evaluation by CD107 + cell frequency flow cytometry 56 Figure 19: Immunofluorescence of CD8 +, Lets and CD107. ........................ 58 Figure 21: Evaluation of cellular composition of patient injuries through histopathological analysis by hematoxylin/eosin coloration. ........................................................................59 Figura 22: Avaliação da composição celular de lesões de pacientes com LTA ..................................60 Figura 23 : Avaliação por microscopia confocal de ETs em lesões de pacientes da forma cutânea da LTA . ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. .............................................................................................. 65.............................................. 55 Figure 18 Evaluation by CD107 + cell frequency flow cytometry 56 Figure 19: Immunofluorescence of CD8 +, Lets and CD107......................... 58 Figure 21: Evaluation of cellular composition of patient injuries through histopathological analysis by hematoxylin/eosin coloration. ........................................................................59 Figura 22: Avaliação da composição celular de lesões de pacientes com LTA ..................................60 Figura 23 : Avaliação por microscopia confocal de ETs em lesões de pacientes da forma cutânea da LTA . ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. .............................................................................................. 65........................ 58 Figure 21: Evaluation of cellular composition of patient injuries through histopathological analysis by hematoxylin/eosin coloration.........................................................................59 Figura 22: Avaliação da composição celular de lesões de pacientes com LTA ..................................60 Figura 23 : Avaliação por microscopia confocal de ETs em lesões de pacientes da forma cutânea da LTA .............................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................. ........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 65.............................................................................................. 65
药物化学在药物原型开发过程中起作用,在这种情况下,它起源于新分子的合成以及表征过程。从这个意义上讲,一组分子一直在对其突出的药理活性产生兴趣,这是Tiosmicarbazonas的类别,在这里强调了其由tiazols组成的核心衍生物。因此,本研究的目的是合成可以呈现药理活性的这类分子的新药理剂。此外,它旨在优化噻唑化合物的合成过程,以及通过二氧化硅分析中的药代动力学特性的确定。作为一种方法,选择了超声合成,具有1:1化学计量比例,用于溶剂,将使用乙醇的使用产生为产品两种编纂的tiazols,例如TZ-03和TZ-04。收入的结果,值分别为70%和98.3%。与二氧化硅分析有关,评估与口服生物利用度和药代动力学表征有关,以及用于吸收,分布,代谢和排泄的数据。除此之外,还由红外线进行,以识别有关化合物组的特定频带。
遵循良好编辑实践的索引期刊的出版物是药学区域的提高和可见性的基础,这对国家的科学和技术发展做出了重大贡献。通过选择在可靠的期刊上发表,作者在其作品中表现出色,以使他们的作品从该地区有能力的同龄人的公认过程中获得科学的信誉,从而确保道德平稳性,有助于其研究的质量和完整性。此外,在受人尊敬的期刊上发表的文章倾向于实现更广泛,更合格的受众,促进对药学科学知识的传播,并积极影响公共卫生,药物教育,药物政策和与化学药品相关的风险管理。因此,理解和仔细应用原则以识别合法杂志成为任何研究人员不仅旨在认识其工作的研究人员的关键步骤,而且还旨在对药物科学的持续进展做出有效贡献。